Vitreomacular interface affects anti-VEGF injection intervals for AMD

PHILADELPHIA β€” The presence of vitreomacular interface appears to significantly affect anti-VEGF injection intervals for treatment of age-related macular degeneration, according to a study presented here. Patients with or without vitreomacular adhesion (VMA) showed similar outcomes, with VMA patients requiring more intensive treatment with a diminished ability to lengthen intervals between injections, Samuel K. Houston III, MD, said at the Wills Eye Annual Conference. β€œThe anatomic factors may contribute to individual treatment responses and should be evaluated and considered in treatment decisions for neovascular AMD,” Houston said.

Full Story β†’